In addition, given the essential roles of PHF8 and CHK1 that act as USP7 substrates in DNA damage response, combination of USP7 inhibitors and chemotherapy/radiotherapy may reduce breast cancer cell resistance (42, 63), which is expected to accelerate the development of breast cancer therapy. Here, USP7 is linked to breast carcinoma.